SCHEMBL6789155

SCHEMBL6789155

CN(C(=O)CC1(O)CCN(Cc2ccccc2)CC1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.47
FAAH O00519 2/20 0.47
CYP2D6 P10635 3/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 2/20 0.46
USP2 O75604 1/20 0.46
CYP3A4 P08684 1/20 0.46
MGLL Q99685 1/20 0.45
TSHR P16473 1/20 0.44
PKM P14618 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR8 P51685 2/20 0.44
KCNH2 Q12809 1/20 0.44
ADAMTS4 O75173 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784761 0.91 CYP2D6 (0.54) DRD4FAAHCYP2D6ALDH1A1CYP3A4
SCHEMBL6783406 0.90 PKM (0.56) DRD4FAAHALDH1A1MAPK1PKM
SCHEMBL6789881 0.89 FAAH (0.51) DRD4FAAHCYP2D6ALDH1A1MAPK1
SCHEMBL6784170 0.88 KMT2A (0.54) DRD4FAAHCYP2D6ALDH1A1MAPK1
SCHEMBL6781033 0.86 FAAH (0.48) DRD4FAAHHRH3GAASMN1; SMN2
SCHEMBL6784345 0.86 DRD4 (0.43) DRD4CYP2D6ALDH1A1MAPK1USP2
SCHEMBL6784382 0.85 FAAH (0.52) DRD4FAAHHRH3GAASMN1; SMN2
SCHEMBL6783277 0.85 DRD4 (0.50) DRD4FAAHCYP2D6CYP3A4LMNA
SCHEMBL6784347 0.84 MAPK1 (0.45) DRD4FAAHCYP2D6ALDH1A1MAPK1
SCHEMBL4482081 0.83 KDM1A (0.44) DRD4CYP2D6ALDH1A1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710060-B2 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-12-12 US disclosed
EP-1182192-A1 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity SCN5A, RYR2, SCN1B DRD4 158/4885FAAH 1196/4885CYP2D6 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.